Mitani Seiji, Hosoda Chihiro, Onodera Yu, Takabayashi Yoko, Sakata Asuka, Shima Midori, Tatsumi Kohei
Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Medicinal Biology of Thrombosis and Hemostasis, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Mol Ther Methods Clin Dev. 2024 Oct 18;32(4):101355. doi: 10.1016/j.omtm.2024.101355. eCollection 2024 Dec 12.
Liver sinusoidal endothelial cells (LSECs) and LSEC progenitor cells (LPCs) derived from human pluripotent stem cells (PSCs) are expected as valuable cell sources for the development of cell therapy for hemophilia A, a congenital deficiency of coagulation factor VIII (FVIII), as LSECs are responsible for FVIII production. However, there is room for improvement in the efficiency of LSEC and LPC differentiation from human PSCs. In this study, we sought to optimize the method of mesoderm differentiation induction, the initial step of LSEC differentiation from human PSCs, to efficiently induce LSEC-like cells capable of secreting FVIII from human induced pluripotent stem cells (iPSCs). Following optimization of the concentration and stimulation period of CHIR99021 (glycogen synthase kinase 3β inhibitor), bone morphogenetic protein 4, fibroblast growth factor 2, and Activin A in the mesoderm induction step, approximately 65% and 54% of cells differentiated into LPCs and LSEC-like cells, respectively. Furthermore, we observed substantial FVIII protein secretion from LSEC-like cells . In conclusion, we established an efficient method for obtaining LPCs and functional LSEC-like cells from human iPSCs .
肝窦内皮细胞(LSECs)和源自人多能干细胞(PSCs)的LSEC祖细胞(LPCs)有望成为治疗甲型血友病(一种先天性凝血因子VIII(FVIII)缺乏症)细胞疗法开发的宝贵细胞来源,因为LSECs负责FVIII的产生。然而,从人PSCs分化出LSEC和LPC的效率仍有提高空间。在本研究中,我们试图优化中胚层分化诱导方法,即从人PSCs分化出LSEC的第一步,以有效地从人诱导多能干细胞(iPSCs)中诱导出能够分泌FVIII的LSEC样细胞。在优化中胚层诱导步骤中CHIR99021(糖原合酶激酶3β抑制剂)、骨形态发生蛋白4、成纤维细胞生长因子2和激活素A的浓度和刺激时间后,分别约有65%和54%的细胞分化为LPCs和LSEC样细胞。此外,我们观察到LSEC样细胞大量分泌FVIII蛋白。总之,我们建立了一种从人iPSCs中获得LPCs和功能性LSEC样细胞的有效方法。